Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  triple-negative breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 67 for your search:
Start Over
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-MBC-001, 2013-000113-20, NCT01881230
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D081CC00006, BIG 6-13, NSABP B-55, NCT02032823
Platinum Based Chemotherapy or Observation in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: EA1131, NCI-2014-01820, U10CA180820, NCT02445391
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: S10-01969, NCT01289353
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCSF Protocol No. 12751, NCT01596751
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: VICC BRE 1287, NCI-2013-01319, NCT01918306
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-032, 2013-002844-10, NCT01928394
Safety Study Of Anakinra Combined With Chemotherapy And Dendritic Cell Vaccine to Treat Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 013-154, NCT02018458
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-494, NCT02041429
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INCB 24360-202, NCT02178722
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0784, NCI-2014-01973, NCT02208375
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1135-CA, NCT02403271
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LJCC 07-03, NCT00542191
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 6628, NCI-2010-00041, P30CA015704, FHCRC-6628, UWCC-6628, UWHSD# 33866, GENENTECH-FHCRC-6628, NCT00733408
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000675211, P30CA022453, WSU-2010-056, 2010-056, NCT01147016
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00019781, WCI1590-08, NCT01194869
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 11174, NCI-2012-00025, NCT01525966
Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 264-12, NCI-2012-01372, P30CA036727, NCT01750073
Ixabepilone and SBRT For Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: STU 102012-020, NCT01818999
Eribulin in HER2 Negative Metastatic BrCa
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-077, NCT01827787
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRAD001 JUST213, 0513-0062, NCT01931163
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01895, 2013C0069, NCI 9455, OSU 13117, 9455, N01CM00070, N01CM00100, P30CA016058, NCT01964924
Cisplatin vs Paclitaxel for Triple Neg
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-383, NCT01982448
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI BRE 203, NCT01990209
Start Over